Neoleukin Therapeutics (United States)

Institution (Company)

Homepage ROR

Also Known As

Neoleukin Therapeutics (United States)

116

Publications

8.8K

Citations

Authors

Concepts

About

Neoleukin Therapeutics (United States) is a company institution in San Bruno, United States known for medicine, immunology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	62	5.6K
2	Natural Sciences	4	27	4.7K
3	Biochemistry	4	15	294
4	Engineering	2	2	41
5	Biomolecular Engineering	1	22	4.6K

Neoleukin Therapeutics (United States)

116

Publications

8.8K

Citations

Page 1

	Year	Citations
De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2 Thomas W. Linsky, Renan Vergara, Jorgen Nelson, Science Viral ReplicationSpike ProteinSynthetic VirologyNatural SciencesSingle Spike Protein	2020	207
Atrasentan in Patients with IgA Nephropathy Hiddo J.L. Heerspink, Meg Jardine, Donald E. Kohan, New England Journal of Medicine	2024	68
The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial Puja Khanna, Paul Maranian, Jeff Gregory, Annals of the Rheumatic Diseases	2009	65
Substrate specificity of lysophosphatidic acid acyltransferase β—evidence from membrane and whole cell assays David Hollenback, Lynn Bonham, Laura Law, Journal of Lipid Research Proteinlipid InteractionLpaat-beta ActivityCellular EnzymologyBiochemistryMedicine	2005	59
The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity Mark Maurer, Katherine E. Lewis, Joseph L. Kuijper, Nature Communications Increased Pd-l1 AffinityImmunologyAnti-tumor ImmunityImmune Cell TherapyImmunotherapy	2022	57
Combination therapy with 2‐difluoromethylornithine and a polyamine transport inhibitor against murine squamous cell carcinoma Yan Chen, Reitha S. Weeks, Mark R. Burns, International Journal of Cancer	2005	43
Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6–12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting Ann Childress, Scott H. Kollins, Andrew J. Cutler, Journal of Child and Adolescent Psychopharmacology	2016	41
<i>De novo</i> design of ACE2 protein decoys to neutralize SARS-CoV-2 Thomas W. Linsky, Renan Vergara, Núria Codina,	2020	38
A multi-centre, blinded, randomised, placebo-controlled, laboratory-based study of MQX-503, a novel topical gel formulation of nitroglycerine, in patients with Raynaud phenomenon Laura K. Hummers, Carin E. Dugowson, Frederick J. Dechow, Annals of the Rheumatic Diseases	2012	37
SBT6050, a HER2-directed TLR8 therapeutic, as a systemically administered, tumor-targeted human myeloid cell agonist. Heather Metz, Monica Childs, Jamie Brevik, Journal of Clinical Oncology Sbt6050 BindImmunologyBiological TherapyInnate ImmunityHer2-directed Tlr8 Therapeutic	2020	30

Page 1